SNARE-dependent glutamate release in megakaryocytes  by Thompson, Catherine J. et al.
Experimental Hematology 2010;38:504–515SNARE-dependent glutamate release in megakaryocytes
Catherine J. Thompsona, Tatjana Schillinga, Martin R. Howardb, and Paul G. Genevera
aDepartment of Biology, University of York, York, United Kingdom; bDepartment of Haematology, York Health Services, National Health Service
Trust, York, United Kingdom
(Received 16 November 2009; revised 12 March 2010; accepted 17 March 2010)Offprint requests t
(Area 9), University o
ac.uk
0301-472X/$–see fron
doi: 10.1016/j.exphObjective. The identification of signalingpathways involved inmegakaryocytopoiesis is essential
for development of novel therapeutics to treat hematological disorders. Following our previous
findings that megakaryocytes express functional channel-forming N-methyl-D-aspartate-type
glutamate receptors, here we aimed to determine the glutamate release capacity in undifferen-
tiated and differentiated megakaryocytes and the role of soluble N-ethyl maleimide-sensitive
factor attachment protein receptor (SNARE) proteins that are known to be associated with
vesicular exocytosis.
Materials and Methods. Using the megakaryocytic cell lineMEG-01, primary megakaryocytes,
and tissue sections of bone marrow, reverse transcription polymerase chain reaction, Western
blot analysis, and immunolocalization were employed to detect factors required for vesicular
glutamate release. Vesicle recycling was monitored by acridine orange and FM1-43 staining
and glutamate release activity was assessed by an enzyme-linked fluorimetric assay. Genetically
modifiedMEG-01 cells, with deletion or overexpression of SNARE and vesicular proteins, were
also examined for glutamate release activity.
Results. We demonstrated that megakaryocytes express numerous proteins required for vesic-
ular glutamate release, including core SNARE proteins, vesicle-associated membrane protein,
soluble N-ethyl maleimide-sensitive factor attachment proteinL23, and syntaxin, as well as
specific glutamate-loading vesicle proteins, VGLUT1 and VGLUT2. Moreover, active vesicle
recycling and differentiation-dependent glutamate release were observed in megakaryocytes.
Vesicle-associated membrane proteinLdeficient MEG-01 cells, which are impaired in vesicle
recycling, showed a 30% decrease in released glutamate, whereas overexpression of VGLUT1
exhibited up to a 2.2-fold increase in glutamate release.
Conclusion. These data show that glutamate release from megakaryocytes occurs in
a SNARE-dependent, exocytotic manner and is increased during differentiation, suggesting
that manipulation of glutamate signaling could influence megakaryocytopoiesis and, therefore,
offer a suitable target for the treatment of thrombosis and other hematological disor-
ders.  2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.Megakaryocytes (MKs) are required for production and
release of platelets (thrombopoiesis). In order to maintain
normal hemostasis, i.e., adequate numbers of platelets circu-
lating in peripheral blood, the c-Mpl ligand thrombopoietin
(TPO) acts as the major hormone controllingmegakaryocyto-
poiesis [1,2]. Numerous additional cytokines, such as stem
cell factor, interleukin-1(IL-1), IL-3, IL-6, IL-11, and granulo-
cyte colony-stimulating factor, are also involved [3,4].
However, the exact cell signaling pathways involved in thiso: Paul G. Genever, Ph.D., Department of Biology
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t matter. Copyright  2010 ISEH - Society for Hematolo
em.2010.03.011process are still to be determined. In addition, there are at least
four recognized TPO-independent signaling mechanisms that
regulate megakaryocytopoiesis: gp130-dependent pathways,
Notch, stromal-derived factor/fibroblast growth factor 4, and
N-methyl-D-aspartate (NMDA)-type glutamate signaling [5].
Glutamate signaling was once thought to be restricted to
the mammalian central nervous system (CNS), where it is
involved in aspects of normal brain function, including
learning, cognition, and memory [6,7]. However, glutamate
signaling networks have been identified in non-neuronal
tissues, such as bone, spleen, lung, liver, pancreas, heart,
stomach, testis, and intestine [8,9]. We have previously re-
ported that primary human MKs, rat bone marrow MKs,
and the MEG-01 megakaryoblastic cell line expressgy and Stem Cells. Published by Elsevier Inc.
505C.J. Thompson et al./ Experimental Hematology 2010;38:504–515functional channel-forming NMDA-type glutamate recep-
tors, and that antagonism of the NMDA receptor by
MK-801 inhibited normal MK development and platelet
production [10,11]. Glutamate transporters, which are
responsible for glutamate uptake, have been identified on
platelets [12,13], and it has been demonstrated that func-
tional a-amino-3-hydroxy-5-methyl-4-isoxazole proprionic
acidtype glutamate receptors are expressed by platelets
and are required for platelet activation [14]. Together, these
findings indicate that glutamate signaling has a fundamental
role in MK development as well as platelet production and
function. However, the local cellular source of the gluta-
mate agonist and the mechanisms that regulate its release
are not known. We hypothesized that MKs were also able
to send glutamate signals using exocytotic mechanisms
similar to presynaptic neurons.
Membrane trafficking in presynaptic nerve terminals in
the CNS is essential for glutamate secretion and involves
biogenesis of specialized vesicles that perform a regulated
cycle of fusion, exocytosis, and regeneration [15,16]. Exocy-
tosis of neurotransmitter is a complex and highly regulated
process involving specific proteinprotein interactions.
The current model is the soluble N-ethyl maleimide-
sensitive factor attachment protein (SNAP) receptor
(SNARE) hypothesis, which proposes that specific vSNARE
proteins on the vesiclemembrane recognize and interact with
the target protein tSNAREs on the plasma membrane of
presynaptic cells [17]. This membrane protein complex is
composed of vesicle-associated membrane protein (VAMP)
alias synaptobrevin (vSNARE) and the tSNARE proteins
syntaxin and SNAP-25 (synaptosomal-associated protein,
25 kDa). These proteins interact with each other in a structur-
ally conserved parallel four-helix bundle, which brings the
vesicle and plasma membranes into close contact so that
they are ready to fuse [18–20]. There are numerous
SNARE-interacting proteins that regulate SNARE complex
assembly and disassembly. SNARE assembly is triggered
by the binding of calcium to a putative calcium sensor, syn-
aptotagmin. This induces the fusion of synaptic vesicles
docked at the active zone close to calcium channels.
Following membrane fusion, disassembly of the SNARE
complex is regulated by two proteins, the ATPase N-ethyl
maleimide-sensitive factor (NSF) and an adapter protein
a-SNAP (solubleNSF attachment protein). SNARE complex
formation is also regulated by syntaxin-interacting proteins,
such as MUNC-18; guanosine triphosphatebinding protein
Rab 3, and Rab 3binding proteins Rabphilin 3, which are
involved in exocytosis via hydrolysis of guanosine triphos-
phate, and vesicular adapter proteins Doc-2 and Mint, which
regulate MUNC-18/syntaxin interactions [21–25]. Specific
transporters expressed on the vesicle membrane determine
the transmitter cargo that will be packaged, carried, and
subsequently released following fusion with the plasma
membrane. The vesicular glutamate transporters (VGLUTs)
are markers of presynaptic glutamatergic neurons and werethought to be restricted to the CNS, where they function to
load glutamate into recycling intracellular vesicles [26–28].
In this study, we demonstrate that MKs express a range
of functional SNARE and related proteins required for
vesicular glutamate exocytosis confirming glutamatergic
signaling activity in MKs, which is further increased after
differentiation.Materials and methods
Plasticware and reagents used for cell culture were purchased
from Life Technologies (Paisley, UK) unless otherwise stated.
Cells were maintained in a humidified atmosphere at 37C in
5% CO2. All cell culture media were supplemented with 100 U/
mL penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine,
unless stated otherwise. All other chemicals were purchased
from Sigma (Dorset, UK), unless stated otherwise.
Cell culture
The MEG-01 megakaryoblastic cell line was maintained in
suspension culture in RPMI-1640 medium and 10% fetal bovine
serum and replated at 1  105 cells/mL with each passaging.
Megakaryocytic differentiation was induced by addition of 100
nM phorbol myristate acetate (PMA) for 72 hours.
Murine and human megakaryocytes
Primary murine MKs (mMKs) were isolated from B6Cba mice as
described previously [29], with minor modifications. Briefly, bone
marrow was flushed out of femora and tibiae with Iscove’s modi-
fied Dulbecco’s medium (Sigma) containing 2% fetal bovine
serum. The suspension was passed through a needle and sieved
through a 100-mm filter. The cell pellet was resuspended in
Opti-MEM supplemented with 5% baby hamster kidney cell
TPO-conditioned media (baby hamster kidney TPO cells engi-
neered to constitutively release TPO were a kind gift from Prof.
Kenneth Kaushansky, UCSD, San Diego, CA, USA) [30]. Mega-
karyocytes were purified after 3 days on a gradient of bovine
serum albumin.
Primary human MKs (hMKs) were generated from hematopoi-
etic progenitor cells in umbilical cord blood obtained with informed
consent as described previously [11]. Briefly, CD34þ cells were iso-
lated by magnetic immunoselection (MACS; Miltenyi Biotec,
Surrey, UK) and cultured in Iscove’s modified Dulbecco’s medium
supplemented with 0.2% (w/v) bovine serum albumin, 1 mM
sodium pyruvate, 1% minimum essential medium nonessential
amino acids, 1% minimum essential medium vitamins, 0.1 mM 2-
mercaptoethanol, 10% cord blood plasma, and 40 ng/mL TPO
(R&D Systems, Abingdon, UK). Cells were plated at 1.5  105
cells/mL, replated after 7 days and cultured for another 7 days.
Transfected MEG-01 cells
Active tetanus toxin light chain contained in the expression
construct pTNT (a kind gift from Dr. S. Sweeney, University of
York, UK [31]) was directionally cloned into pcDNA3.1/V5-HIS
B (Invitrogen, Carlsbad, CA, USA). Primers used to generate
the VGLUT1 constructs were: 50-ttagcagatctcaggagccgccaccat-30
and 50-gattacgtcgacgggaggcacatggtctgtag-30 with a 1 base-pair
mismatch in the reverse primer to allow for fusion with enhanced
green fluorescent protein (EGFP) encoded in pEGFP-N2
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ally cloned into this vector. VGLUT1 was also directionally
cloned into pcDNA3.1/V5-HIS B using the following primers:
50-ttagcagatctacaggagccgccaccat-30 and 50-gattacggtaccgggaggca-
catggtcagtag-30. MEG-01 cells were transiently transfected using
Lipofectamine 2000 reagent (Invitrogen) according to the manu-
facturer’s instructions. The pGL3-luciferase plasmid (Promega,
Southampton, UK) was used to determine transfection efficiency.
Immunolocalizations
Cryosections of tibiae and femora from neonatal rats were fixed in
4% paraformaldehyde and exposed to 3% hydrogen peroxide to
deplete endogenous peroxidase activity. After blocking with appro-
priate serum, sectionswere incubatedwith primary antibodies (anti-
VGLUT1, anti-VGLUT2, antiSNAP-23, all Synaptic Systems,
Coventry, UK; antisyntaxin 4 and anti-CD61, both BD Biosci-
ences, Oxford, UK) followed by corresponding biotinylated
secondary antibodies (Vector Laboratories, Peterborough, UK).
Sections were then exposed to an avidin-biotinylated peroxidase
reagent (ABC Elite; Vector Laboratories) prior to visualization of
peroxidase activity using 3,30-diaminobenzidine. Sections were
counterstained with Mayer’s hematoxylin before mounting in
glycerol/phosphate-buffered saline. Negative controls received the
same concentration of an appropriate immunoglobulin G (Vector
Laboratories) in place of primary antibody.
For immunofluorescent localization of SNARE complex and
associated proteins in MEG-01 cells and mMKs, cytospins were
fixed in 4% paraformaldehyde, blocked with appropriate serum,
and incubated with primary antibodies (anti-VGLUT1, anti-Table 1. Primer sequences
Gene, species
a-SNAP, h/m AGGCTCATCC
g-SNAP, h CACCTCGCCA
g-SNAP, m GATGCTGAAG
GAPDH, h/m GGTGAAGGT
MUNC-13, h AAGGCAGAA
MUNC-13, m GCCTAAGTGT
MUNC-18, h/m GACCTGTCCC
NSF, h/m GCTCAGTTGT
Rab3A, h CGTCCTTCCT
Rab3A, m AAGGTCAAA
Rab3B, h GTTCACCCCC
Rab3B, m ACCTCCTTCC
Rabphillin3A, h/m GGAGCCAGC
SNAP-23, h AGAAGATGA
SNAP-23, m GCAAGGGGA
SNAP-25, h GGTATCAGGA
SNAP-25, m GTTATGTTGG
Syntaphilin, h/m GCGCACCTCT
Syntaxin 1a, h/m GAGGAGGTG
Syntaxin 4, h CAGGAGTTGG
Syntaxin 4, m AGTGGGCAG
VAMP1, h/m ACCCAGGCAC
VAMP3, h TGGACAAGG
VAMP3, m TGGACAAGG
VGLUT1, h GCCTCCCTCG
VGLUT2, h/m TGGACATGGT
VGLUT3, h TGCAATAAGT
VGLUT3, m ACTTTGAGGAVGLUT2, antiSNAP-23, anti-synaptotagmin, all Synaptic
Systems; antisyntaxin 4, BD Biosciences; and anti-VAMP1/2,
Sigma). Antibody binding was determined using corresponding
fluorescein isothiocyanateconjugated secondary antibodies
(anti-rabbit fluorescein isothiocyanate; Santa Cruz, Heidelberg,
Germany; anti-mouse fluorescein isothiocyanate; Sigma). Samples
were mounted in Vectashield mounting medium containing 40,6-
diamidino-2-phenylindole (Vector Laboratories) and imaging
was performed using a confocal laser scanning microscope (Carl
Zeiss, Welwyn Garden City, UK).
Western blot analysis
MEG-01 cells, primary hMKs, and human brain homogenates
(Abcam, Cambridge, UK) were lysed using 20 mM Tris (pH 7.5),
150 mM NaCl, 1 mM ethylene diamine tetraacetic acid, 1 mM
ethylene glycol tetraacetic acid, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerol phosphate, 1 mM NaVO4, and 1
mg/mL leupeptin, separated by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis and transferred onto a nitrocellulose
membrane. After blocking with 4% skim milk powder in TBS-T
(20 mM Tris, 137 mM NaCl, 0.1% Tween 20), membranes were
incubated with primary antibodies (anti-VAMP1/2; Sigma,
antiSNAP-23; Synaptic Systems, antisyntaxin 4; BD Biosci-
ences, antiglyceraldehyde phosphate dehydrogenase; Advanced
ImmunoChemical, Long Beach, CA, USA). After washing and
incubation with the corresponding horseradish peroxidaseconju-
gated secondary antibodies (Santa Cruz), specific antibody binding
was detected using enhanced chemiluminescent solution and
Hyperfilm (GE Healthcare, Little Chalfont, UK).Forward and reverse primer
AAAATAGAGGAAGCA, AGCCACCTTCAGCAGACACTTGTT
AAGCAGAGAAATACC, AGTGCCGCCTCATCAAACCTACG
GAGATGCAGAAGCTG, ACTGCCGTTAAAGCCTGGTATGCTG
CGGWGTCAACGG, GGTCATGAGYCCTTCCACGAT
CAGCAGGAGGA, GGACACTACATCACCCACAACC
GGAGGTGTGGAACAA, GGCTGGGTAGTCGTGTGGTAAGGAG
AGATGCTGAAGAA, GAGGTGAGCCATGTTGGTGATG
GTGGTTGTGGATGAC, GCTGCTCTCCTGTGGCAATGTT
CTTCCGCTATGCT, TGACACCACCCGCTCATCCTC
ACCATCTACCGCAACG, CCTCAAAGAACTCAAAGCCCAGGTG
AGCCTTCGTTAGCAC, GCCTGCCTTACACTGATGTTCTCCTTT
TTTTCCGCTATGCTG, TGCCTCACACTGATGTTCTCCTTGG
AAGTCCAACAAGC, CCATGTCCGGTTTCAGCCAGAG
AATGGAAGAGAACCTG, CTGTTGGTGTCAGCCTTGTC
ACAACTAAATCGCATA, TCCATCTCATCTTCTCTGGCATCATT
CTTTGGTTATGTTGGATG, TGGTTTTGTTGGAATCAGCCTTCT
ATGAGCAAGGCGAAC, ATCTGGCGATTCTGGGTGTCAAT
CCACCTGTGA, GAGCCGGTCCTGTGTGTCCTT
AAGCGGAAGCACAG, AGAGGCAAAGATGGCGGGGTTC
AGAAACAGCAGGTCA, ATCAGACACCATCCCAGCATTGG
AGTGAGGTGTTTGTGT, CCAATGATGACAGCCAAGATGAGAA
AAGTGGAGGAGGT, CAATAACTACCACGATGATGGCACAGA
TTCTGGAAAGAGACCA, TGAAGAGACAACCCACACGATGATGATG
TTCTGGAAAGAGACCA, ACACTGATCCCTATCGCCCACATCT
CCGCTACATTATCG, CGCCGCCAGGGAGTGCTA
CAACAACAGCA, GCATAGGAACCACAAAAGGAGGT
AAGGTGGGTCTCTTGTC, GCTATGAGGAACACATTCTGCCATT
GGTCTTTGGATTTGC, TCTCTCTGTTGTCTCCACTCGGTCT
Figure 1. Expression of soluble N-ethyl maleimide-sensitive factor attachment protein receptor (SNARE) complex and accessory genes by megakaryoc
Reverse transcription polymerase chain reaction was used to determine messenger RNA expression of SNARE complex and accessory proteins in MEG
cells (left panel), primary murine megakaryocytes (MKs, middle panel) and primary human MKs (right panel). For MEG-01 cells, expression in the un
ferentiated (phorbol myristate acetate [PMA]), as well as differentiated (þPMA) state is shown. Human fetal forebrain or mouse whole brain was use
a positive control. Negative controls (no reverse transcriptase [RT] and water) were performed in parallel.
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Figure 2. Western blot analysis of soluble N-ethyl maleimide-sensitive factor attachment protein receptor (SNARE) complex proteins in megakaryocytes.
Expression of SNARE complex proteins SNAP-23, Syntaxin 4, and vesicle-associated membrane protein (VAMP) was determined by Western blot analysis in
MEG-01 cells, in the undifferentiated (phorbol myristate acetate [PMA]), as well as differentiated (þPMA) state, and in primary human megakaryocytes
(MK).Human brain (HB) lysatewas used as a positive control, detection of glyceraldehyde phosphate dehydrogenase (GAPDH)was performed as loading control.
508 C.J. Thompson et al. / Experimental Hematology 2010;38:504–515Reverse transcriptase-polymerase chain reaction (PCR)
Total RNA was extracted from MEG-01 cells, hMKs, and mMKs
using TRIzol reagent (Invitrogen). Complementary DNA was
synthesized using SuperScript II reverse transcriptase (Invitrogen)
and used for PCR with gene-specific primers (Sigma; Table 1).
PCR was performed for 35 cycles of 94C for 10 seconds,annealing temperature for 20 seconds, and 72C for 1 minute.
PCR products were sequenced to confirm their specificity.
Acridine orange and FM1-43 staining
Acidic vesicles were stained with 5 mg/mL acridine orange in
culture medium. After 15 minutes at 37C, the cells were pelleted
and washed with phosphate-buffered saline prior to imaging.
Figure 3. Immunolocalization of soluble N-ethyl maleimide-sensitive factor attachment protein receptor (SNARE) complex and accessory proteins in megakar-
yocytes. (A) Immunofluorescent localization of SNARE complex and accessory proteins (green) was determined by confocal laser scanning microscopy inMEG-
01 cells in theundifferentiated (phorbolmyristate acetate [PMA]) aswell as differentiated (þPMA) state, nucleiwere stainedwith 40,6-diamidino-2-phenylindole
(blue); the bottom row showsnegative controls for vesicle-associatedmembrane protein (VAMP) andSyntaxin (mouse immunoglobulinG) and for Synaptotagmin,
SNAP-23, vesicular glutamate transporter (VGLUT) 1, and VGLUT2 (rabbit immunoglobulin G) immunostainings, as well as the overexpression of enhanced
green fluorescent protein (EGFP)-VGLUT1 in undifferentiated (PMA) MEG-01 cells and empty vector control (EGFP con); arrows indicate elevated accumu-
lation of VGLUT1 and VGLUT2 at the cell periphery in differentiatedMEG-01 cells as well as dense distribution of VGLUT1 in specific regions near the plasma
membrane of VGLUT1-transfected cells; bar 5 20 mm. (B) Brown staining reports expression of SNARE complex proteins (Syntaxin 4 and SNAP-23) and
VGLUT1/2, respectively, in rat bone marrow. Detection of CD61 was used to confirm megakaryocyte identity. Nuclei were counterstained with hematoxylin
(blue); bar5 30 mm.
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described previously [32]. Briefly, MEG-01 cells and mMKs
were plated at 5  104 cells/cm2 onto coverslips and cultivated
for 24 hours. Cells were washed with Hank’s buffered saline
solution (HBSS) containing 1 mM CaCl2. Recycling vesicles
were labeled using 10 mM FM1-43 (Invitrogen) for up to 20
minutes. Cells were washed in HBSS and fixed in 4% parafor-
maldehyde prior to imaging. For destaining experiments,
MEG-01 cells were stained with FM1-43 for 20 minutes, washed
in HBSS and incubated for 30 to 60 minutes in FM1-43-free
HBSS.
Glutamate release assay
Glutamate release was determined using an enzyme-linked fluori-
metric assay based on previously published protocols [33] with
some modifications [32]. Briefly, cells were plated at 5  105
cells/mL in blackened 96-well plates (Greiner, Stonehouse, UK)
in release buffer, containing 120 mM NaCl, 3 mM KCl, 1.25
mM NaH2PO4, 25 mM HEPES-Na, 4 mM glucose, 1 mM
MgCl2, and 2 mM CaCl2 (pH 7.4). The reaction was initiated after
30 minutes by the addition of 40 U/mL glutamate dehydrogenase
and 1 mM NADPþ. Fluorescence for samples and standards of
known concentrations of exogenous glutamate were monitored
using a fluorescence plate reader (Dynex Technologies, Worthing,
UK) with a thermostated incubation chamber (37C). To deter-
mine intracellular glutamate concentrations, cells were incubated
with 0.1% Triton X-100 before performing the assay. Glutamate
release was normalized to cell number and statistically analyzed
by one-way analysis of variance.Results
Expression of SNARE complex and accessory proteins in
megakaryocytes
MEG-01 cells, mMKs, and hMKs expressed SNARE
complex and essential accessory components on the gene
transcription and protein level (Figs. 1–3). Messenger
RNA expression of core complex proteins VAMP1 and
syntaxin 4 were identified in MEG-01 cells treated with
and without PMA and in primary MKs (Fig. 1). Expression
of SNAP-25 was not found but its homologue SNAP-23
was identified. The accessory proteins NSF, Rab 3A,
MUNC-13, MUNC-18, a-SNAP, and g-SNAP were
expressed in MEG-01 cells treated with and without
PMA, and in primary MKs. SNAP-23, VAMP, and syntaxin
4 expression was confirmed by Western blot analysis
(Fig. 2) in MEG-01 cells, treated with and without PMA,
and hMKs. SNARE and accessory proteins were also iden-
tified at the protein level in MEG-01 cells and primary MKs
using immunofluorescent localization (Fig. 3A) and immu-
nohistochemistry (Fig. 3B). Cytoplasmic VGLUT1 and
VGLUT2 were identified in MEG-01 cells and rat bone
marrow MKs, with occasional dense distribution at the
cell periphery. Similarly, in MEG-01 cells overexpressing
EGFP-tagged VGLUT1, the localization was preferentially
located in specific regions near the plasma membrane,compared to generalized, diffuse distribution in EGFP-
only controls (Fig. 3A).
Identification of acidic vesicles in megakaryocytes
Acidic, synaptic-like vesicles were identified in MKs using
the cell-permeable, pH-sensitive dye acridine orange. After
being trapped in acidic vesicles, acridine orange exhibits
red emission, whereas green fluorescence occurs in its
soluble form or when bound to double-stranded DNA
[34,35]. In MEG-01 cells, red fluorescence was observed
around the periphery of the cells, and green fluorescence
within the cytosol (Fig. 4A). Acidic vesicles were also
detected in hMK cells, where green and red fluorescence
colocalized in the cytosol, while red fluorescence alone
was observed in the periphery of the cells (Fig. 4B).
Identification of vesicular recycling in megakaryocytes
Vesicle recycling activity was shown in mMKs by FM1-43
staining. FM1-43 integrates into the plasma membrane of
cells, is incorporated into the vesicle membrane as vesicles
fuse with the plasma membrane and acts as a fluorescent
reporter of vesicle recycling. The accumulative increase
in the amount of fluorescent dye within the cells over
a 20-minute incubation period corresponded to the uptake
of vesicles (Fig. 4C). The loss of fluorescence following
removal of FM1-43 reported exocytosis of these vesicles.
Glutamate release by megakaryocytes and its regulation
by the SNARE complex
MEG-01 cells and primary MKs spontaneously released
glutamate, which was significantly enhanced in differenti-
atedMEG-01 cells compared to cells without PMA treatment
(Fig. 5A). To determine whether the SNARE complex is
responsible for glutamate release from MKs, depletion and
overexpression of SNARE-associated proteins were as-
sessed. Firstly, the effect of tetanus toxin, which cleaves
VAMP to disable vesicle recycling by preventing the forma-
tion of the SNARE complex [36], was examined. Treatment
of MEG-01 with tetanus toxin decreased VAMP protein in
MEG-01 cells in the absence and presence of PMA
(Fig. 5B). Transient transfection of MEG-01 cells with
tetanus toxin induced a 30%decrease (p! 0.001) in released
glutamate (Fig. 5C). MEG-01 cells overexpressing the
VGLUT1 protein showed a 2.26- and 1.69-fold increase (p
! 0.001) of released glutamate and a 2.29- and 1.69-fold
elevation (p ! 0.001) of intracellular glutamate, respec-
tively, when compared to the respective vector control
(pcDNA3.1/V5-His B and pEGFP-N2) (Fig. 5D).Discussion
We have demonstrated that MKs have the ability to release
glutamate in a manner similar to presynaptic neurons in the
CNS involving SNARE-dependent exocytosis. Several
components of the core exocytotic complex and accessory
proteins are the same as those identified in the CNS as
Figure 4. Identificationof acidic, recyclingvesicles inmegakaryocytes. (A)After acridineorange staining, acidicvesicleswereobserved in theMEG-01cells (red)
in the periphery of the cells. Green fluorescence reports soluble dyewithin the cytosol. (B) Acidic vesicles were also observed in primary human megakaryocytes
(MKs), where additionally to their localization at the periphery of the cells (red), they colocalizedwith soluble dye in the cytosol of the cell (yellow); bars5 20mm.
(C) Vesicular recycling in primary murine MKs was detected by incorporation of the FM1-43 dye into vesicle membranes during endocytosis, which leads to an
increase of green fluorescence within the cells. Following FM1-43 removal, the cells destained within 60 minutes reporting exocytosis of these vesicles.
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SNAP-25, which is present in the SNARE complex in
neuronal cells, expression of its homologue tSNARE
SNAP-23, which is vital for membrane fusion and vesicle
docking in non-neuronal tissues [38], has been found in
MKs. SNARE complex factors were also identified on the
protein level inMKs. Consequently, the detection of SNARE
complex factors and accessory proteins not only in cell
cultures but also in sections of bone marrow, i.e., in situ,
supports our results obtained by using a MK cell line and
primary MKs. As one of the core proteins of the SNARE
complex, VAMPwas detected byWestern blotting at approx-
imately 36 kDa in MKs corresponding to its homodimeric
form, whereas additionally, a monomeric VAMP band (18
kDa) and a 68-kDa band, according to literature correspond-
ing to VAMP/synaptophysin heterodimers, were identified in
the human brain lysate control [22,39].Expression of VGLUT1 and VGLUT2 in MKs suggests
that these vesicular glutamate transporters play a role in
MKs similar to that seen in the CNS, where they are required
for the uptake of glutamate into synaptic vesicles in
glutamate-releasing neurons [40]. We observed immunoloc-
alization of endogenous VGLUT proteins in both primary
MKs and MEG-01 cells, as well as localization of EGFP-
tagged VGLUT1 inMEG-01 cells prominently at the plasma
membrane consistent with vesicular release activity identi-
fied in peripheral specialized zones in neuronal cells [27].
Furthermore, overexpression of VGLUT1 in MEG-01 cells
significantly increased the amount of glutamate released.
Previous in vitro studies have detected increased glutamate
release at synapses of VGLUT1-overexpressing glutamater-
gic neurons [41] and overexpression of Drosophila VGLUT
in motoneurons in vivo has been reported to augment vesic-
ular glutamate release, with an increase in synaptic vesicle
Figure 5. Glutamate release in megakaryocytes. (A) After 72 hours of cultivation, an enzyme-linked fluorimetric assay was used to detect glutamate release
from MEG-01 cells in the undifferentiated (phorbol myristate acetate [PMA]) as well as differentiated (þPMA) state and from primary murine and human
megakaryocytes (MKs) (n 5 3, mean þ standard deviation; ***p! 0.001). (B) Western blot analysis (evaluated by densitometry normalized to the house-
keeping protein glyceraldehyde phosphate dehydrogenase [GAPDH]) demonstrated that treatment with 100 nM tetanus toxin decreased vesicle-associated
membrane protein (VAMP) protein levels in MEG-01 cells in the undifferentiated (PMA; 45% decrease compared to undifferentiated control) as well
as differentiated (þPMA; 94% decrease compared to differentiated control) state, which inhibits formation of the SNARE complex. (C) Using the
enzyme-linked fluorimetric assay with MEG-01 cells overexpressing the tetanus toxin light chain (TeTxLC) demonstrated a 30% reduced glutamate release
as a result of the inhibition of the SNARE complex due to reduction of VAMP compared to empty vector control (pcDNA3.1/V5-His B; n 5 3, mean þ
standard deviation; ***p ! 0.001).
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maintain normal levels of excitation at the synapses [42].
These data confirm the specificity of our findings and that
glutamate signaling in MKs is at least in part VGLUT-
dependent.
Endocytosis and exocytosis of acidic vesicles inMKswere
monitored using the pH-sensitive dye acridine orange, as has
been described for acidic neurotransmitter-containing vesi-
cles in synaptosomes [43]. In neuronal cells, glutamate
loading acidifies recycling synaptic vesicles and the simulta-
neous uptake of acridine orange results in red fluorescence.With exocytosis, this dye is released from synaptosomes,
which decreases red fluorescence, while green fluorescence
of the dye reports its nonvesicle-associated form. In both
MEG-01 cells and hMKs, we identified abundant acidic
vesicles in the cytosol with mainly peripheral localization in
MEG-01 cells. Moreover, we employed FM1-43, a styrylpyr-
idinium dye, to observe vesicle recycling, as has been shown
for synaptosomal recycling in a range of species, including
mouse, frog, and rat [44–47]. The incorporation of FM1-43
dye into MKs during a 20-minute time course indicates that
vesicular endocytosis takes place within MKs. Destaining
Figure 5. (Continued.) (D) Two different transfectionvectors (pcDNA3.1/V5-HISB and pEGFP-N2)were used to introduceVGLUT1 overexpression intoMEG-
01 cells. Glutamate released fromVGLUT-overexpressing cells, as well as intracellular glutamatewas detected by an enzyme-linked fluorimetric assay. Compared
to empty vector controls (pcDNA3.1/V5-His B and pEGFP-N2, respectively), glutamate release was 2.26- and 1.69-fold increased and intracellular glutamatewas
2.29- and 1.69-fold elevated in pcDNA3.1/V-HisB hVGLUT1- and pEGFP-N2 hVGLUT1-transfected cells, respectively (n5 3, mean þ SD; ***p! 0.001).
513C.J. Thompson et al./ Experimental Hematology 2010;38:504–515experiments, i.e., removal of the dye from the culture
medium, caused a reduction of fluorescence, which provides
evidence for vesicular exocytosis. Taking the results of both
acridine orange and FM1-43 staining into account, they
provide evidence that acidic neurotransmitter-containing
vesicles are present in megakaryocytes and that they are
participating in active vesicle recycling, as described for
neuronal cells.
We next determined if megakaryocytes released gluta-
mate in a SNARE-dependent manner similar to neurotrans-
mitter release in synaptosomes [17,18,20,37]. Depletion of
VAMP, which is mandatory for the formation of the SNARE
complex [36], decreased glutamate exocytosis, whereas
VGLUToverexpression increased SNARE glutamate release
by stimulating the loading of glutamate into intracellular
vesicles [26–28,48].
Furthermore, in mature megakaryocytes, which were
obtained by differentiation of MEG-01 cells with PMA,
VGLUT1 protein was more prominent in the differentiated
state and glutamate release was significantly elevated.
Recently, Isakari et al. [49] confirmed that treatment of
MEG-01 cells with PMA can be used as a model of human
megakaryopoiesis and platelet production. Their gene
expression study also revealed elevated messenger RNA
levels for SNAP-23 within 24 hours of differentiation. We
observed SNAP-23 expression at the RNA, as well as on
the protein level in both undifferentiated and differentiated
MEG-01 cells after 72 hours of PMA treatment; however,
we could not detect differential expression. This could be
due to the different time points examined, but nevertheless
confirms the activity of SNARE-associated factors during
megakaryocytopoiesis.
The identification of key regulatory proteins, namely the
putative calcium sensor synaptotagmin and Rab3A, in MKs
provides evidence for Ca2þ-dependent regulation ofvesicular glutamate exocytosis in these cells. Via real-
time glutamate-release monitoring, we could demonstrate
that MKs released glutamate in the presence of Ca2þ.
However unlike neuronal cells, MKs are classified as non-
excitable cells and are not believed to express voltage-gated
Ca2þ channels [50–52]. Voltage-gated Ca2þ channels
enable rapid influx of Ca2þ as a fast response to an
incoming stimulus, leading to neurotransmitter release.
During this process, an intracellular linker that associates
with synaptic proteins like synaptotagmin provides a tight
interaction between presynaptic Ca2þ channels and the
SNARE complex, which is essential for stabilizing neuro-
transmitter release [53]. Therefore, even though MKs
express Ca2þ-permeable NMDA glutamate receptor, our
observations suggest that glutamate release mechanisms
in MKs are different than those described for neurons;
MKs rather seem to spontaneously release glutamate,
which is increased during differentiation. This further
implies that factors regulating the passive and active exocy-
tosis of glutamate, respectively, play an important role
during MK differentiation and should be addressed in
future work.
In conclusion, our previous studies have shown that
NMDAglutamate receptor signalingwithinMKs is important
for megakaryocytopoiesis and platelet production in vitro
[10,11]. Here, we provide strong evidence that SNARE-
dependent glutamate-release mechanisms, similar to but
distinct from those identified in the CNS, are present in
MKs. The release of glutamate fromMKs provides a cellular
source of glutamate within the bone marrow compartment,
which can potentially activate their NMDA glutamate recep-
tors in an autocrine fashion controlling megakarocytopoiesis
and platelet production. Moreover, we have previously
shown that osteoblastic cells also express SNARE-
associated and accessory proteins and are able to release
514 C.J. Thompson et al. / Experimental Hematology 2010;38:504–515glutamate [32,54]. This indicates that the osteoblastic cells
provide an additional source of glutamate for the MKs and
that both cell typesmay interact in the bonemarrow.Together,
these findings suggest that SNARE-dependent glutamate
signaling plays a critical role inMK development and platelet
production and may represent a route for novel therapeutic
approaches to maintain normal hemostasis, for example, by
generating anti-thrombotic agents.Acknowledgments
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